Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

References

• Sutherland DJ. Hormones and cancer. In: The Basic Science of Oncology. Tannock IF, Hill RP (Eds). Pergamon Press, NY, USA 204–222 (1987).
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Belhocine T, Steinmetz N, Hustinx R et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res.8(9), 2766–2774 (2002).
   PubMed Web of Science ®Google Scholar
• De Saint-Hubert M, Prinsen K, Mortelmans L et al. Molecular imaging of cell death. Methods48(2), 178–187 (2009).
   PubMed Web of Science ®Google Scholar
• Thomson DM, Krupey J, Freedman SO et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl Acad. Sci. USA64(1), 161–167 (1969).
   PubMed Web of Science ®Google Scholar
• Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol. Clin. North Am.30(4), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Gion M, Mione R, Barioli P et al. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res.16(4B), 2279–2284 (1996).
   PubMed Web of Science ®Google Scholar
• Ghanem G, Loir B, Morandini R et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int. J. Cancer94(4), 586–590 (2001).
   PubMed Web of Science ®Google Scholar
• Beck EP, Moldenhauer A, Merkle E et al. CA 125 production and release by ovarian cancer cells in vitro. Int. J. Biol. Markers13(4), 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Stigbrand T. The versatility of cytokeratins as tumor markers. Tumour Biol.22(1), 1–3 (2001).
   PubMedGoogle Scholar
• Linder S. Cytokeratin markers come of age. Tumour Biol.28(4), 189–195 (2007).
   PubMedGoogle Scholar
• Cocco RE, Ucker DS. Distinct modes of macrophage recognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure. Mol. Biol. Cell12(4), 919–930 (2001).
   PubMed Web of Science ®Google Scholar
• Brouckaert G, Kalai M, Krysko DV et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell15(3), 1089–1100 (2004).
   PubMed Web of Science ®Google Scholar
• Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol.60, 619–642 (1998).
   PubMed Web of Science ®Google Scholar
• Chang YS, di Tomaso E, McDonald DM et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA97(26), 14608–14613 (2000).
   PubMed Web of Science ®Google Scholar
• Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res.34, 997–1004 (1974).
   PubMed Web of Science ®Google Scholar
• Swartz MA, Kristensen CA, Melder RJ et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br. J. Cancer81(5), 756–759 (1999).
   PubMed Web of Science ®Google Scholar
• Larson CJ, Moreno JG, Piento KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A62(1), 46–53 (2004).
   PubMedGoogle Scholar
• Linder S, Havelka AM, Ueno T et al. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett.214(1), 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Hou JM, Greystok A, Lancashire L et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol.175(2), 808–816 (2009).
   PubMed Web of Science ®Google Scholar
• Moll R. Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochemica. Suppl.41, 117–127 (1991).
   PubMedGoogle Scholar
• Björklund B. Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Antibiot. Chemother.22, 16–31 (1978).
   PubMedGoogle Scholar
• Weber K, Osborne M, Moll R et al. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re- evaluation of a human tumor marker. EMBO J.3(11), 2707–2714 (1984).
   PubMed Web of Science ®Google Scholar
• Rydlander L, Ziegler E, Bergman T et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur. J. Biochem.241(2), 309–314 (1996).
   PubMedGoogle Scholar
• Stieber P, Hasholzner U, Bodenmuller H et al. CYFRA 21–1. A new marker in lung cancer. Cancer72(3), 707–713 (1993).
   PubMed Web of Science ®Google Scholar
• Chou CF, Riopel CL, Rott LS et al. A significant soluble keratin fraction in ‘simple’ epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J. Cell Sci.105(Pt 2), 433–444 (1993).
   PubMed Web of Science ®Google Scholar
• Nishibori H, Matsuno Y, Iwaya M et al. Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin-conjugated cytokeratin 8 fragments. Cancer Res.56(12), 2752–2757 (1996).
   PubMed Web of Science ®Google Scholar
• Bergman AC, Benjamin T, Alaiya A et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis21(3), 679–686 (2000).
   PubMed Web of Science ®Google Scholar
• Olofsson MH, Cummings J, Fayad W et al. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark.5(3), 117–125 (2009).
   PubMed Web of Science ®Google Scholar
• Sundström BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int. J. Biol. Markers9(2), 102–108 (1994).
   PubMedGoogle Scholar
• Cummings J, Ranson M, Butt F et al. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother. Pharmacol.60(6), 921–924 (2007).
   PubMed Web of Science ®Google Scholar
• Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol.138(6), 1379–1394 (1997).
   PubMed Web of Science ®Google Scholar
• Ku NO, Liao J, Omary MB. Apoptosis generates stable fragments of human type I keratins. J. Biol. Chem.272(52), 33197–33203 (1997).
   PubMed Web of Science ®Google Scholar
• Leers MP, Kölgen W, Björklund V et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol.187(5), 567–572 (1999).
   PubMed Web of Science ®Google Scholar
• Kramer G, Erdal H, Mertens HJ et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res.64(5), 1751–1756 (2004).
   PubMed Web of Science ®Google Scholar
• Hägg M, Biven K, Ueno T et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest. New Drugs20(3), 253–259 (2002).
   PubMed Web of Science ®Google Scholar
• Ueno T, Toi M, Bivén K et al. Measurement of an apoptosis product in the sera of breast cancer patients. Eur. J. Cancer39, 769–774 (2003).
   PubMed Web of Science ®Google Scholar
• Demiray M, Ulukaya EE, Arslan M et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest.24(7), 669–676 (2006).
   PubMed Web of Science ®Google Scholar
• Koelink PJ, Lamers CB, Hommes DW et al. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer9, 88 (2009).
   PubMedGoogle Scholar
• Ausch C, Buxhofer-Ausch V, Olszewski U et al. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur. J. Surg. Oncol.35(11), 1164–1168 (2009).
   PubMed Web of Science ®Google Scholar
• Ulukaya E, Yilmaztepe A, Akgoz S et al. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer56(3), 399–404 (2007).
   PubMed Web of Science ®Google Scholar
• Kramer G, Schwarz S, Hagg M et al. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br. J. Cancer94(11), 1592–1598 (2006).
   PubMed Web of Science ®Google Scholar
• de Haas EC, di Pietro A, Simpson KL et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia10(10), 1041–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Ozturk B, Coskun U, Sancak B et al. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int. Immunopharmacol.9(5), 645–648 (2009).
   PubMed Web of Science ®Google Scholar
• Dive C, Smith RA, Garner E et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br. J. Cancer102(3), 577–582 (2010).
   PubMed Web of Science ®Google Scholar
• Scott LC, Evans TR, Cassidy J et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br. J. Cancer101(3), 410–417 (2009).
   PubMed Web of Science ®Google Scholar
• Olofsson MH, Ueno T, Pan Y et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res.13(11), 3198–3206 (2007).
   PubMed Web of Science ®Google Scholar
• Cummings J, Hodgkinson C, Odedra R et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol. Cancer Ther.7(3), 455–463 (2008).
   PubMed Web of Science ®Google Scholar
• Micha D, Cummings J, Shoemaker A et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin. Cancer Res.14(22), 7304–7310 (2008).
   PubMed Web of Science ®Google Scholar
• Koopman G, Reutelingsperger CP, Kuijten GA et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood84(5), 1415–1420 (1994).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene22(47), 7414–7430 (2003).
   PubMed Web of Science ®Google Scholar
• Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev.20(1), 1–15 (2006).
   PubMed Web of Science ®Google Scholar
• Berndtsson M, Hagg M, Panaretakis T et al. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer120(1), 175–180 (2007).
   PubMed Web of Science ®Google Scholar